Litcius/Paper detail

Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial

David W. Kimberlin, Inmaculada Aban, Kalyani Peri, Javier K. Nishikawa, Jolanta Bernatoniene, Marieke Emonts, Nigel Klein, Alasdair Bamford, Roberta L. DeBiasi, Saul N. Faust, Christine E. Jones, Paddy McMaster, Mary T. Caserta, Amina Ahmed, Mike Sharland, Gail J. Demmler‐Harrison, Scott Hackett, Pablo J. Sánchez, Fiona Shackley, Dominic F. Kelly, Penelope H. Dennehy, Gregory A. Storch, Richard J. Whitley, Paul Griffiths

2024The Journal of Pediatrics33 citationsDOIOpen Access PDF

Topics & Concepts

ValganciclovirMedicineSensorineural hearing lossPlaceboRandomized controlled trialHearing lossCytomegalovirusInternal medicinePediatricsGanciclovirAudiologyHuman cytomegalovirusHerpesviridaeViral diseaseImmunologyVirusAlternative medicinePathologyCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsOcular Diseases and Behçet’s Syndrome